



PPD Named “Best CRO” at Vaccine Industry Excellence Awards

WILMINGTON, N.C. (May 6, 2021) – PPD, Inc. (Nasdaq: [PPD](#)) was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress. Accelerated Enrollment Solutions (AES), a business of PPD, received the honor of “highly commended” in the category of “Best Clinical Trial Network.”

“When it comes to helping customers develop safe and effective vaccines, our dedicated experts are passionate about bringing their expertise to advance vaccine development to help people the world over,” said William Sharbaugh, chief operating officer of PPD. “The global pandemic demonstrated that our investments in vaccine-research capabilities positioned PPD well to support the urgent need for COVID-19 vaccines. This prestigious recognition is a testament to the ingenuity, commitment and drive of our global employees to help our customers save lives and create a healthier future.”

PPD was recognized as the best CRO for its end-to-end suite of clinical development services in core therapeutic areas, including a unit dedicated solely to vaccines, and the introduction and extension of new services, including digital clinical trial solutions. [PPD[®] Laboratories](#) offers specialized vaccine capabilities and has worked with 13 vaccines approved by the U.S. Food and Drug Administration. With more than 25 years of government and commercial vaccine experience, PPD has local expertise across 90 countries on six continents.

In 2020, in response to the pandemic, PPD invested in the development of new clinical study models to improve the patient experience by reducing the number of in-person visits in favor of remote and digitally enabled study participation, in order to improve patient recruitment and retention. PPD continues to support multiple customers’ COVID-19 research programs.

AES was commended for its ability to deliver high-quality data, predictable enrollment for clinical trials and the introduction of new services across its network. AES has successfully supported multiple, diverse clinical trials for various vaccines during the pandemic and capitalized on the efficiencies of its network to provide quality outcomes for customers.

The 2021 ViE recognition builds on PPD’s momentum in winning the 2020 ViE Award for “Best Central/Specialty Laboratory” for PPD Laboratories’ central lab. PPD Laboratories provides comprehensive central and specialized vaccine lab support for all trial phases, including safety, efficacy and immunogenicity testing, as well as development consulting services.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 27,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.

PPD Contacts

Media:

Nadine Maeser

+1 919 456 4425
media@ppd.com

Investors:
Tracy Krumme
+1 910 558 4186
investors@ppd.com

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the planned acquisition of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are available on our website at <https://investors.ppd.com> or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

###